Your browser doesn't support javascript.
loading
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
Chae, Chang-Suk; Teran-Cabanillas, Eli; Cubillos-Ruiz, Juan R.
Afiliação
  • Chae CS; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
  • Teran-Cabanillas E; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Cubillos-Ruiz JR; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Cancer Immunol Immunother ; 66(8): 969-977, 2017 Aug.
Article em En | MEDLINE | ID: mdl-28214928
Immune-based therapies that induce remarkable and durable responses against melanoma and lung cancer have unfortunately demonstrated limited success in ovarian cancer patients. This is likely due to the exceptional immunoregulatory nature of ovarian tumors, which employ numerous strategies to effectively suppress anti-tumor immunity. Here, we summarize a decade of research indicating that ovarian cancers possess an exquisite capacity to subvert the activity of host dendritic cells (DCs) as a key mechanism to impede the development and maintenance of protective T cell-based immune responses. Identifying, understanding, and disabling the precise mechanisms promoting DC dysfunction in ovarian cancer are, therefore, fundamental requirements for devising the next generation of successful immunotherapies against this devastating malignancy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células Dendríticas / Vacinas Anticâncer / Células Supressoras Mieloides / Imunoterapia Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células Dendríticas / Vacinas Anticâncer / Células Supressoras Mieloides / Imunoterapia Idioma: En Ano de publicação: 2017 Tipo de documento: Article